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The relatively short history of linkage studies in bipolar disorders (BPs) has produced inconsistent ﬁndings. Im-
plicated regions have been large, with reduced levels of signiﬁcance and modest effect sizes. Both phenotypic and
genetic heterogeneity may have contributed to the failure to deﬁne risk loci. BP is part of a spectrum of apparently
familial affective disorders, which have been organized by severity. Heterogeneity may arise because of insufﬁcient
data to deﬁne the spectrum boundaries, and, in general, the less-severe disorders are more difﬁcult to diagnose
reliably. To address the inherent complexities in detecting BP susceptibility loci, we have used restricted diagnostic
classiﬁcations and a genetically more homogeneous (Ashkenazi Jewish) family collection to perform a 9-cM auto-
somal genomewide linkage scan. Although they are genetically more homogeneous, there are no data to suggest
that the rate of illness in the Ashkenazim differs from that in other populations. In a genome scan of 41 Ashkenazi
pedigrees with a proband affected with bipolar I disorder (BPI) and at least one other member affected with BPI
or bipolar II disorder (BPII), we identiﬁed four regions suggestive of linkage on chromosomes 1, 3, 11, and 18.
Follow-up genotyping showed that the regions on chromosomes 1, 3, and 18 are also suggestive of linkage in a
subset of pedigrees limited to relative pairs affected with BPI. Furthermore, our chromosome 18q22 signal (D18S541
and D18S477) overlaps with previous BP ﬁndings. This research is being conducted in parallel with our companion
study of schizophrenia, in which, by use of an identical approach, we recently reported signiﬁcant evidence for a
schizophrenia susceptibility locus in the Ashkenazim on chromosome 10q22.
Introduction
Bipolar disorders (BPs [MIM125480]) are relatively com-
mon and disabling diseases of variable expression, with
apparent phenotypic as well as etiologic heterogeneity.
The Diagnostic and Statistical Manual, fourth edition
(DSM-IV), recognizes several forms of BP (i.e., bipolar I
disorder [BPI], bipolar II disorder [BPII], cyclothymia,
and BP not otherwise speciﬁed [BP NOS] [American Psy-
chiatric Association 1994]). These vary in the extent of
disability and the characterization of the periods with
manic and/or depressive episodes. Estimates of lifetime
prevalence for BPI have been reported to vary between
0.4% and 1.6%, and, for BPII, the prevalence has been
reported to be ∼0.5% (American Psychiatric Association
1994), although some controversy exists, with other es-
timates as high as 5%, depending on the diagnostic cri-
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teria used (Akiskal 2002). Evidence from family, twin,
and adoption studies strongly supports a genetic com-
ponent of BP, with heritability estimates of 58%–74%
(Tsuang and Faraone 1990) and risk to ﬁrst-degree rela-
tives of 5%–10% (Craddock and Jones 1999). The mean
age at onset is 28 years; however, onset has also been
observed in children, as well as in adults in their 6th and
7th decades (Stone 1989; Goodwin and Jamison 1990).
Relatives of probands with earlier ages at onset appear
to be at increased risk for BP (Weissman et al. 1984;
Coryell et al. 2001; Grigoroiu-Serbanescu et al. 2001;
Todd 2002). Although segregation analyses have been
inconclusive, they suggest a complex and multigenic sus-
ceptibility to BP, involving both genes and environment.
Intensive efforts to identify or localize susceptibility genes
for BP have yielded neither signiﬁcant associations for
disease genes themselves nor strong consensus about
linkage regions. Genetic-linkage ﬁndings in at least 11
independent regions have reached genomewide signiﬁ-
cance ( ) in single studies: 4p16 (Blackwood et al.P ! .05
1996), 5q (Sklar et al. 2003), 6q16 and 17q25 (Dick et
al. 2003), 6q22 (Middleton et al. 2004), 8q24 (McInnis
et al. 2003b), 12q (Morissette et al. 1999), 13q (Detera-
Wadleigh et al. 1999), 16p (Ekholm et al. 2003;McInnis
et al. 2003a), 18q (Schulze et al. 2003), and 22q12 (Kel-
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soe et al. 2001). However, these ﬁndings do not consis-
tently replicate across the 29 genome scans reported in
the past 2 decades. The two meta-analyses conducted
thus far also failed to support overlapping regions: Bad-
ner and Gershon (2002) identiﬁed regions on chromo-
somes 13q and 22q, whereas Segurado et al. (2003) iden-
tiﬁed regions on chromosomes 9p, 10q, and 14q (Segur-
ado et al. 2003).
The reasons for such inconsistencies are likely the com-
plex etiology of BP and the genetic heterogeneity present
in most linkage samples. Several genes acting in concert
may be responsible for BP in some families, whereasother
genetic combinations may be the source of the suscep-
tibility among others. If true, linkage studies to date have
unwittingly combined families of different genetic etiolo-
gies into one analysis. One approach to reduce hetero-
geneity is to study families from a relatively genetically
isolated population that has emerged from a small num-
ber of founders (McKusick 1973; Ekelund et al. 2000;
McGinnis et al. 2002). This increases the likelihood that
the families in the sample will have a similar underlying
genetic predisposition, improving the ability to detect
the effects of a particular gene. Previous genetic linkage
studies of BP have employed this approach, analyzing
a limited number of multiplex pedigrees from, for ex-
ample, the Old Order Amish of Pennsylvania, Portugal,
Costa Rica, Finland, Scotland, and Canada (Saguenay–
Lac-St.-Jean) and such population isolates are recom-
mended for both linkage disequilibrium (LD)–based
screening and ﬁne mapping of BP genes, if reasonably
large samples can be collected (Escamilla 2001).
An additional strategy to reduce heterogeneity is to
improve the precision of phenotype classiﬁcation and
thus reduce misclassiﬁcation. For example, studies of BP
have often included BPI, BPII, recurrent unipolar de-
pression, and schizoaffective disorder diagnoses as “af-
fected,” under an assumption that these diagnoses re-
ﬂect a common genetic predisposition. If they do, this
broad-phenotype approach will provide the greatest
power. However, this may be detrimental for at least two
reasons: (1) the etiologies underlying each classiﬁcation
may be distinct, and “lumping” washes out effects of
any particular signal; and (2) the misclassiﬁcation rates
for each diagnosis category may be quite different. Re-
stricting the affected phenotype to the diagnosis that
provides the greatest conﬁdence can reduce noise.
With these considerations of heterogeneity in mind,
we have conducted a genome scan in a set of Ashkenazi
Jewish families who are affected with BP, ﬁrst consid-
ering as affected all individuals with BPI and their rela-
tives with either BPI or BPII and then restricting our
analyses to only pedigrees with relative pairs affected
with BPI (DSM-IV). The current Ashkenazi Jewish popu-
lation lives mostly in central and eastern Europe and
the United States and is descended from a small founder
population established ∼500 years ago (Ostrer 2001).
The close genetic relationship of Ashkenazi descendants
has been documented through traces of several Men-
delian genetic disorders, as well as through Y-chromo-
some and mitochondrial similarities (Tikochinski et al.
1991; Santachiara Benerecetti et al. 1993; Hammer et
al. 2000; Nebel et al. 2000, 2001). Genetic studies among
the Ashkenazim have been productive in the identiﬁca-
tion of susceptibility genes for several disorders, given
the reduced genetic variation. Founder mutations have
been shown to be important as causes of colorectal can-
cer (Foulkes et al. 2002; Niell et al. 2003), breast cancer
(Struewing et al. 1997), and prostate cancer (Foulkes
et al. 2002) in the Ashkenazim, and mutations in the
identiﬁed genes (MSH2, BRCA1, andBRCA2) have been
shown to be important for disease susceptibility in other
non-Ashkenazi populations (Neuhausen et al. 1998;
Lynch et al. 2004). Even though the rates of BPI and BPII
among the Ashkenazim do not appear to differ from
other populations, focusing on this isolate can reduce
heterogeneity in linkage analyses and increase the utility
of association analyses. Our analysis of all 41 families,
as well as a BPI-restricted subset, allowed us to gain
information from the entire set, under the assumption of
shared genetic vulnerability, and to gain signal in the
subset, given the reliability of the BPI diagnosis and the
potential for increased genetic homogeneity.
Material and Methods
Ascertainment of Study Subjects
Ashkenazi Jewish families with members affectedwith
BPI were recruited nationally over a 6-year period through
advertisements in newspapers and Jewish newsletters,
talks to community organizations, letters to leaders of
the Jewish community, and a studyWeb site (JohnsHop-
kins Epidemiology/Genetics Program in Psychiatry Home
Page). Families were eligible for inclusion in these analyses
if the proband met DSM-IV criteria for a BPI diagnosis
and a ﬁrst- or second-degree relative met DSM-IV cri-
teria for BPI or BPII. Our ascertainment strategy for the
multiply affected pedigrees was to examine directly all
potentially affected individuals (including those with
BPI, BPII, any psychotic disorder, and those with any
hospitalization for a psychiatric problem), the parents
of those individuals, and any other family members con-
necting the affected pairs. Rules for extending a pedigree
included initially obtaining family history information
about all ﬁrst- and second-degree relatives of the pro-
band and all ﬁrst-degree relatives of other affected in-
dividuals in the family. When any parent of an affected
individual was unavailable, we sought at least one un-
affected sibling for DNA samples.
206 Am. J. Hum. Genet. 75:204–219, 2004
Diagnostic Instruments and Procedures
Potentially affected individuals and their parents were
examined in person by a doctoral-level clinical psycholo-
gist (clinical examiner) and were asked for a blood sam-
ple. All recruitment methods and protocols for the col-
lection of blood samples and clinical data were approved
by the Johns Hopkins University institutional review
board, and appropriate informed consent was obtained
from all human subjects. The data collection for this study
was done in tandem with a similar study focusing on
Ashkenazi Jewish families with schizophrenia (SZ [MIM
181500]) (Fallin et al. 2003). All diagnostic procedures
for data collection were identical. Examiners were blind
to the proband’s diagnosis. Therefore, they did not know
if the family was being recruited for the study of BP or
SZ. Most of the subjects were seen in their homes. The
Diagnostic Interview for Genetic Studies, version 2.0
(DIGS; revised for DSM-IV) (see National Institutes of
Mental Health [NIMH] Center for Genetic Studies Web
site), a semistructured interview to elicit information
about lifetime history of psychiatric symptoms and be-
haviors, was used. As part of the interview process, a
psychiatric-treatment history was prepared, and each
subject was asked to sign release forms allowing copies
of his or her psychiatric-treatment records to be made
available to our research team. Interviews were tape-
recorded for quality-control purposes and for review by
members of a Consensus Diagnostic Committee, who
assigned the ﬁnal diagnosis for each subject (see below).
To decrease measurement error, in addition to inter-
viewing the subject, the clinical examiner also inter-
viewed an informant about the subject. The clinical ex-
aminer completed a written diagnostic formulation for
each case, describing prominent features and the course
of illness.
Final diagnoses were assigned through a consensus pro-
cedure. Information available about each subject (e.g.,
the tape-recorded interview, interview booklets, a sum-
mary of information obtained from informant, the clini-
cal examiner’s diagnostic formulation, and psychiatric-
treatment records) was reviewed independently by two
members (psychiatrists or doctoral-level clinicalpsycholo-
gists) of a Consensus Diagnostic Committee, who each
ﬁlled out a DSM-IV diagnostic checklist. The checklist
contained each necessary criterion for 26 Axis I DSM-IV
disorders. Disorders were rated as absent, possibly pre-
sent, probably present, deﬁnitely present, or unknown.
The age at onset for disorders rated as present (for any
level of certainty) was also recorded. Ratings were as-
signed independently by the two members of the com-
mittee and were then compared. If disagreement existed
with respect to (1) the ratings of any of the 26 diagnoses
(including certainty levels assigned), (2) the age at onset
(14-year discrepancy) for any of the disorders that were
rated as positive, or (3) course-of-illness ratings for in-
dividuals with psychotic symptoms, then the two mem-
bers of the committee met to resolve the discrepancies.
Demographic and Clinical Characteristics
Ancestry questionnaires were completed for each pro-
band to establish the country or region of origin of the
proband’s parents and four grandparents and to reduce
the possibility of non-Ashkenazi grandparents or foun-
ders in our sample. Eastern Europe (Russia, Poland, Lat-
via, Lithuania, and Estonia) and central Europe (Austria,
Germany, Hungary, the Czech Republic, Slovakia, Ser-
bia, and Romania) account for 199% of the known
countries of origin among grandparents in the 41 pedi-
grees. Families were excluded from these analyses if any
grandparent of an affected subject was known to be of
non-Ashkenazi descent.
The family structures and phenotypes for our data set
are provided in ﬁgure 1. The families consisted mostly
of affected sibling pairs (ASPs). Four families contained
affected cousin pairs, six families contained affected avun-
cular pairs, and one family had a grandparent-grand-
child affected pair. Among the total set of 41 families,
affected individuals included those with BPI (76.3%)
and BPII (23.7%). Twenty-six families contained at least
two members with BPI. Of these 26, 22 families con-
tained relative pairs with BPI that were informative for
linkage. These 22 families were used in the BPI-restricted
subanalysis, denoted “BPI subset,” and are shown in the
top half of ﬁgure 1. Of the affected individuals in the
41 families, 46% were male. The average age at onset
for all affected individuals was 25.5 years (range, 5–76
years), and the average age at onset among the 22 fami-
lies in the BPI subset was 24.7 years (range, 14–69 years).
In the larger data set of 41 pedigrees, 34 individuals were
classiﬁed as “phenotype unknown” in all analyses, be-
cause they were given one of the following consensus
diagnoses: major depression without comorbid anxiety
disorders ( ), major depression with comorbidnp 17
anxiety disorders ( ), cyclothymia ( ), possiblenp 6 np 1
BPII ( ), schizophrenia/schizoaffective disordernp 3
( ), or schizophrenia spectrum personality disordernp 6
( ). For the smaller BPI subset analyses, there wasnp 1
one family with a sibling who had a diagnosis of BPII,
in addition to the two siblings with BPI. This BPII sibling
was classiﬁed as “phenotype unknown.”
Genotyping
All genotyping for this scan was performed at the
Australian Genome Research Facility (AGRF). The auto-
somal scan included 382 markers (ABI Prism Linkage
Mapping Set, version 2 [MD-10]), with an average spac-
ing of 8.85 cM, covering 3,381 cM, and an average
heterozygosity of 0.785. The largest gaps were 24.1 cM
Figure 1 Structure and phenotypes of Ashkenazi pedigrees with BP. “*dna*” indicates DNA available for the subject. Phenotypes are
indicated as follows: BPI p bipolar I disorder; BPII p bipolar II disorder; SZ p schizophrenia; SZA p schizoaffective disorder; FH p
diagnosis based on family history data; UP p unipolar depression; and UNK p unknown phenotype.
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on chromosome 8q12.1 and 23.8 cM on 6p21.31. Map
order and distances were determined from the Ge´ne´thon
map. Markers were genotyped in 28 multiplexed panels.
All PCR reactions were performed under standard con-
ditions in a total volume of 6 ml by use of a PTC-225
DNA Engine Tetrad (MJ Research). Primers were labeled
with the ﬂuorescent dyes FAM,HEX, andNED (Applied
Biosystems LMSV2). PCR products were then pooled
into multiplex panels ranging from 10 to 20 markers
and electrophoresed for 2.8 h (0.2 mm denaturing poly-
acrylamide gels, 4.5%) on an Applied Biosystems 377
DNA Sequencer. GeneScan software (Applied Biosys-
tems) assigns tracking for each sample lane. Files are
then imported into Genotyper (Applied Biosystems) soft-
ware that interprets the electropherogram and assigns
genotypes.
When possible, follow-up markers were chosen from
the ABI linkage mapping set (LMS-HD5); otherwise, they
were chosen from the Marshﬁeld map (Marshﬁeld Cen-
ter for Medical Genetics Web site) or from published
literature (Brzustowicz et al. 2000; Schulze et al. 2003).
For each region, markers were chosen to achieve doubled
density in the 1-LOD linkage interval (increasing infor-
mation content to ∼90%, on average). Priority was given
to markers with the highest heterozygosity. Map order
and distance were based on the July 2003 human ge-
nome assembly available through the University of Cal-
ifornia–Santa Cruz Genome Browser (UCSC Genome
Bioinformatics Web site). In total, 27 follow-up markers
were successfully genotyped (8 each on chromosomes 1
and 11, 6 on chromosome 3, and 5 on chromosome 18).
Statistical Analyses
Mendelian inconsistencies and potential relationship
errors were evaluated and corrected prior to data analy-
sis by use of the Pedmanager (version 0.9) interface at
AGRF (Ewen et al. 2000). The AGRF software was also
used for binning of alleles, and Genehunter, version 2.0,
was used to identify double (ﬂanking) crossovers in hap-
lotypes. Markers were removed from subsequent analy-
ses for the entire family when Mendelian inconsistencies
were apparent and were removed for individuals when
apparent double crossovers were identiﬁed in Gene-
hunter haplotypes. Parametric and model-free allele-
sharing linkage analyses were performed by use of the
software Genehunter (Kruglyak et al. 1996). Parametric
LODs and heterogeneity LOD (HLOD) scores were cal-
culated for both dominant and recessive models. Param-
eters for these models are noted in table 1. Model-free
allele sharing was assessed via the nonparametric linkage
(NPL) statistic on the basis of estimated allele sharing for
all affected relative pairs (ARPs) in the data set. Marker-
allele frequencies among the Ashkenazimwere estimated
on the basis of founders from 60 Ashkenazi pedigrees
collected for our psychiatric-genetics studies (101 par-
ents from families with BPI or SZ, according to DSM-
IV criteria). This allowed a more precise estimate of fre-
quencies than relying on founders in the 41 families with
BPI. However, parents were available for most of our
families (see ﬁg. 1), so the impact of these allele-fre-
quency estimates should not be large.
Two data sets and phenotype classiﬁcations were used
for the linkage scan. First, all 41 families were included.
For these analyses, individuals with a deﬁnite or probable
diagnosis of BPI or BPII were considered “affected”; in-
dividuals in these families with certain other psychiatric
diagnoses (speciﬁed above) were classiﬁed as “phenotype
unknown.” This resulted in 97 affected individuals and
54 ARPs (38 ASPs). The second data set was a subset
that included only the families with at least one infor-
mative ARP in which both individuals were identiﬁed
as having BPI. This subset contained 22 families, with
52 individuals affected with BPI and 33 ARPs (19 ASPs).
For these analyses, only those with a deﬁnite or probable
diagnosis of BPI were considered “affected”; individuals
affected with BPII and the other above-speciﬁed psychi-
atric disorders were classiﬁed as “phenotype unknown.”
Parent-of-origin effects were incorporated into the
parametric linkage analyses by use of the Genehunter
imprinting (GHI) software, which allows different het-
erozygote penetrances depending on parental inheritance
of the disease allele (Strauch et al. 2000). In this soft-
ware, “maternal imprinting” refers to masking the ma-
ternal alleles, such that the paternal allele is expressed
in the offspring (i.e., paternal inheritance), and “paternal
imprinting” reﬂects the opposite. Model-free parent-of-
origin effects for ASPs were estimated via the method
of Holmans (2003) by use of parent-speciﬁc identical-
by-descent (IBD)–sharing estimates derived from output
from the GENIBD component of the SAGE software
package, version 4.5 (SAGE 2003).
Empirical P values were calculated for the NPLall scores
via simulation. The program MERLIN (Multipoint En-
gine for Rapid Likelihood Inference) (Abecasis et al. 2002)
was used to generate 50,000 replicates of families iden-
tical to those in our sample. Markers with similar allele
sizes and frequencies were also generated under the as-
sumption of no linkage. Linkage analyses were then per-
formed on these unlinked replicates (following the pro-
cedure of Li and Haghighi [1999]), and genomewide em-
pirical P values were estimated by extrapolating results
for chromosome 1 to the whole-genome level, assuming
chromosome 1 represents 1/10 of the genome. For ﬁne
mapping, chromosomewide empirical P values were cal-
culated as the proportion of 50,000 replicates showing
an equal or more extreme NPL score at any point on the
chromosome. Although recessive and dominant model
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Table 1
Maximum Linkage Signal for Each Chromosome at Initial Genome Scan for 41 Multiplex BPI-BPII Ashkenazi Pedigrees
CHROMOSOME
RESULTS OF PARAMETRIC ANALYSIS FOR
RESULTS OF MODEL-FREE ANALYSIS Dominant Modela Recessive Modelb
Location
(cM)
Peak
Marker
Information
Content
at Peak NPL P
Location
(cM)
Maximum
HLOD a
Location
(cM)
Maximum
HLOD a
1 167.3 D1S484 .74 2.464 .0072 167.3 1.73 .65 219.4 1.01 .27
2 151.0 D2S151 .72 2.165 .0157 153.32 1.54 .61 138.88 .72 .28
3 57.1 D3S1277 .79 2.223 .0135 59.7 1.44 .61 119.6 .80 .28
4 31.3 D4S419 .74 1.890 .0300 33.7 .71 .43 38.5 1.31 .41
5 202.7 D5S408 .62 1.413 .0796 202.7 .33 .27 202.7 .49 .24
6 117.16 D6S276 .74 2.066 .0203 113.28 1.48 .55 22.5 .51 .21
7 3.9 D7S531 .85 1.915 .0284 137.28 .25 .27 139.32 .37 .24
8 67.5 D8S285 .73 1.166 .1224 67.5 .30 .25 67.5 .97 .31
9 9.3 D9S286 .85 1.233 .1094 5.58 .69 .37 156.8 1.23 .39
10 117.8 D10S185 .81 1.970 .0251 127.7 .99 .43 26.02 .56 .26
11 58.0 D11S4191 .86 2.347 .0099 58.00 .37 .27 59.26 1.96 .44
12 31.9 D12S364 .87 1.085 .1394 35.14 .38 .30 31.9 .48 .22
13 15.10 D13S171 .78 1.358 .0881 15.10 .66 .37 88.2 .03 .05
14 40.2 D14S288 .82 1.358 .0880 40.20 .44 .30 40.2 .63 .23
15 69.2 D15S131 .85 1.086 .1394 58.06 .19 .21 69.2 .73 .27
16 41.6 D16S3068 .79 1.201 .1156 41.60 .16 .19 38.0 .72 .27
17 125.0 D17S784 .76 .068 .4706 … … … … … …
18 109.8 D18S61 .77 2.224 .0136 103.2 .36 .33 109.8 1.08 .38
19 29.2 D19S226 .81 1.338 .0912 31.72 .60 .39 21.9 .10 .09
20 51.6 D20S195 .82 1.326 .0932 51.60 .37 .27 … … …
21 41.3 D21S266 .65 .883 .1887 33.74 .38 .33 0 .50 .29
22 49.7 D22S274 .72 .383 .3496 … … … 49.7 .54 .23
NOTE.—NPL scores 12.2 are shown in bold italics. a p estimated proportion of linked families at this location.
a Dominant parametric HLOD scores, calculated in Genehunter, version 2.0, assumed a disease allele frequency of .005 and penetrances of
.65, .65, and .0096 for homozygotes, heterozygotes, and noncarriers, respectively.
b Recessive parametric HLOD scores, calculated in Genehunter, version 2.0, assumed a disease allele frequency of .11 and penetrances of .65,
.0096, and .0096 for homozygotes, heterozygotes, and noncarriers, respectively.
parametric analyses were also performed for each chro-
mosome, our main focus has been on model-free NPL-
score results, and we therefore focused on this statistic
for P-value estimation. Furthermore, these additional
parametric tests are correlated (on average) with the NPL
results and are not likely to increase the overall type 1
error greatly.
The location of the unobserved trait locus, along with
the 95% CI, was estimated for regions of follow-up ge-
notyping on chromosomes 1, 3, 11, and 18 via Gene-
Finder software (Liang et al. 2001), which uses IBD in-
formation from all available ASPs. The estimated mean
proportion of alleles that were shared IBD ( ) and thepˆ
SEs for this estimation were obtained by use of the GEN-
IBD and SIBPAL components of the SAGE software
package (SAGE 2003).
Results
Initial Autosomal Scan Linkage Analyses
NPL and HLOD plots across the entire genome for
the full set of 41 families and for the subset of 22 BPI-
restricted families are shown in ﬁgure 2. No initial link-
age signal reached “signiﬁcant” evidence for linkage,
according to the criteria of Lander and Kruglyak (1995),
in the 41 families or in the subset of BPI-BPI pairs. The
highest NPL and parametric LOD signals on each chro-
mosome are shown in tables 1 and 2 for the overall sample
and BPI-restricted set. The highest signal across the au-
tosomes among all families was observed on chromo-
some 1q23.3 (D1S484), with an NPL score of 2.46 and
a dominant maximum HLOD score of 1.73. This NPL
score corresponds to a genomewide P value of .8 on the
basis of simulations. Given the limited power of our study,
an NPL score of 3.29 would be needed to achieve
empirical genomewide signiﬁcance at the .05 level in
these data, according to simulations. Considering this,
we chose a liberal threshold of NPL 12.2 for genotyping
additional markers in a region to increase the marker
density in our data set. Three other peaksmet this thresh-
old in the overall set and were considered for follow-up
of additional markers: chromosomes 3p23 (NPLp
at D3S1277), 11q12.1 ( at D11S4191),2.22 NPLp 2.35
and 18q22.2 ( at D18S61). In the BPI sub-NPLp 2.22
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Figure 2 Genome scan for all of the families with BPI or BPII and for the BPI-restricted subset. NPL score is shown in black, dominant
HLOD in red, and recessive HLOD in blue.
set, chromosome 3p23 had an NPL score of 2.46 (also
at D3S1277), corresponding to an empirical genome-
wide P value of .77. No other peaks met our threshold
for follow-up in the subset analysis.
Additional Linkage Analyses, with Increased Marker
Density in Four Regions
Additional markers in four regions were genotyped
and analyzed in both the larger data set of 41 pedigrees
and in the subset of 22 pedigrees. Results after addition
of markers to double the density in each of these regions
are shown in table 3. Although, as expected, the infor-
mation content improved by ∼10% in each region, we
found that there was little change in the results in the
overall set of 41 families, except for an increase of 0.58
in the NPL score on 1q23 (top half of table 3) (estimated
location 171.8 cM [95% CI 160.0–183.7 cM]). How-
ever, several changes are worth noting in the 22-family
BPI subset (bottom half of table 3). The NPL score on
1q23.3 from the initial analyses in the 22 families was
only 1.87. However, since the whole set of families was
genotyped at additional markers in this region, we were
able to run follow-up linkage in the subset as well. On
follow-up, the increased marker density provided an
NPL score of 3.05 (estimated location 169.4 cM [95%
CI 154.6–184.2 cM]). A similar increase was observed
for the parametric analyses (the HLOD score increased
from 1.18 to 2.03) on chromosome 1q23.3. Also, the
signal on chromosome 3 improved in the BPI subset
(estimated location 57.4 cM [95% CI 49.0–65.8 cM])
but did not increase in the full data set. Linkage in chro-
mosome 18 in the BPI subset also increased substantially:
the NPL score increased from 1.79 to 2.44 (estimated
location 106.2 cM [95% CI 96.5–115.8 cM]). In addi-
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Table 2
Maximum Linkage Signal for Each Chromosome at Initial Genome Scan for 22 Multiplex BPI-Restricted Ashkenazi Pedigrees
CHROMOSOME
RESULTS OF PARAMETRIC ANALYSIS FOR
RESULTS OF MODEL-FREE ANALYSIS Dominant Modela Recessive Modelb
Location
(cM)
Peak
Marker
Information
Content
at Peak NPL P
Location
(cM)
Maximum
HLOD a
Location
(cM)
Maximum
HLOD a
1 167.3 D1S484 .72 1.867 .0324 167.3 1.18 .82 32.9 .94 .44
2 140.9 D2S112 .72 1.852 .0336 142.92 .89 .64 136.86 1.07 .50
3 57.1 D3S1277 .79 2.457 .0077 59.7 1.36 .82 53.10 1.52 .70
4 43.3 D4S391 .81 1.419 .0797 57.3 .23 .29 36.10 .48 .38
5 202.7 D5S408 .63 1.189 .1186 40.3 .26 .35 202.70 .66 .36
6 164.3 D6S1581 .64 1.606 .0558 162.3 .84 .53 154.30 .70 .36
7 143.4 D7S530 .82 1.509 .0673 144.8 .22 .33 127.92 .82 .51
8 0 D8S264 .72 1.385 .0846 0 .46 .43 0 .67 .34
9 9.3 D9S286 .83 1.546 .0629 9.3 .71 .48 156.8 .88 .45
10 117.8 D10S185 .82 1.074 .1424 153.24 .35 .33 63.86 .39 .31
11 10.6 D11S1338 .79 1.403 .0820 10.6 .23 .31 146.7 .40 .31
12 31.9 D12S364 .85 1.739 .0427 35.14 .57 .47 31.9 1.32 .52
13 24.1 D13S218 .75 1.290 .1000 24.10 .71 .50 48.9 .09 .14
14 40.2 D14S288 .82 1.538 .0637 96.9 .50 .51 40.2 .85 .43
15 69.2 D15S131 .84 1.234 .1101 63.68 .09 .19 67.82 .41 .33
16 60.6 D16S415 .84 1.845 .0340 60.6 .39 .43 60.6 .57 .35
17 125.0 D17S784 .76 .071 .5240 15.0 .05 .09 90.0 .05 .06
18c 6.0 D18S63 .75 1.796 .03802 6.0 .71 .50 47.76 .97 .52
19 29.2 D19S226 .83 2.060 .0210 36.76 1.20 .81 21.9 .71 .40
20 51.6 D20S195 .84 1.400 .0823 52.78 .83 .52 49.08 .07 .15
21 41.3 D21S266 .67 .654 .2558 22.00 .21 .29 0 .19 .21
22 9.00 D22S539 .77 .495 .6862 … 0 0 49.7 .02 .08
NOTE.—NPL scores 12.2 are shown in bold italics. a p estimated proportion of linked families at this location.
a Dominant parametric HLOD scores, calculated in Genehunter, version 2.0, assumed a disease allele frequency of .005 and penetrances of
.65, .65, and .0096 for homozygotes, heterozygotes, and noncarriers, respectively.
b Recessive parametric HLOD scores, calculated in Genehunter, version 2.0, assumed a disease allele frequency of .11 and penetrances of
.65, .0096, and .0096 for homozygotes, heterozygotes, and noncarriers, respectively.
c Secondary peak at 109.8 cM (peak marker, D18S61; information content at peak, .72; NPL score, 1.792; P p .0382).
tion, CIs were computed for the secondary peak on chro-
mosome 18 at 18p11 for BPI-BPII pedigrees; the peak
CI was 9.84 cM (0.0–30.37 cM). These observed in-
creases in evidence for linkage, especially for chromo-
somes 1 and 18, most likely demonstrate an increase in
power as a result of increased marker density when re-
lying on a small data set.
It is important to point out that, despite the smaller
sample size, these improvements occurred among the re-
stricted BPI-only analyses. For the chromosome 1, 3, and
18 signals, the mean IBD estimates ( ) were actuallypˆ
higher for this restricted set than for the overall set of
families: chromosome 1 location, versus 0.63;pˆp 0.70
chromosome 3 location, versus 0.61; chromo-pˆp 0.68
some 18p location, versus 0.59; and chromo-pˆp 0.68
some 18q location, versus 0.60. This supportspˆp 0.68
our strategy of increasing homogeneity in phenotype.
Parent-of-Origin (P-O-O) Analyses of Chromosome 18
Non-Mendelian P-O-O effects have been observed for
rare disorders such as Prader-Willi and Angelman syn-
dromes, and there is evidence that P-O-O effects contrib-
ute to common complex diseases such as diabetes (Huxt-
able et al. 2000) and Alzheimer disease (Bassett et al.
2002). P-O-O effects for BP have been proposed, both
on the basis of family data that suggest an increased risk
of illness for maternal relatives of a BP proband (Mc-
Mahon et al. 1995) and on the basis of genetic data that
suggests paternal imprinting (McMahon et al. 2001;
McInnis et al. 2003a).
Considering the previous evidence for a BP locus on
18q22, as well as previous reports of P-O-O effects for
this signal (McInnis et al. 2003c), we also performed
P-O-O analyses in our data. Parametric analyses incor-
porating parental origin for penetrance of heterozygotes
(see ﬁg. 3) showed strong evidence for paternal inheri-
tance (labeled as “maternal imprinting” in the ﬁgure)
across the 18p11.3 region that has been previously
linked to BP, but only weak evidence in the chromosome
18q22 region. Allele-sharing analyses incorporating
P-O-O effects were conducted on 38 ASPs in 34 pedi-
grees and also showed evidence for paternal inheritance
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Figure 3 P-O-O analyses of chromosome 18 for all of the families with BPI or BPII. For the GHI analyses, dominant models identical
to those in table 3 were used, with the exception that alleles from the imprinted parent were given a penetrance equal to that of noncarriers.
“Maternal imprinting” for parametric analyses denotes increased penetrance of the paternal allele and therefore is analogous to paternal sharing.
along most of the chromosome, including the 18p re-
gion. It is interesting that the best P-O-O signal was near
the centromere (D18S1102, chromosome 18q12), at
a region showing no linkage when P-O-O was not con-
sidered. The signal at this site results from strong over-
sharing of paternal alleles (estimated proportion of pa-
ternal/maternal alleles shared IBD, 0.74/0.26). Similar
model-free P-O-O results were obtained by use of the
“parent of origin” option for concordant ASPs in the
LODPAL component of SAGE (data not shown).
Discussion
We have performed the ﬁrst genome scan for BP-suscep-
tibility loci among an Ashkenazi Jewish sample of multi-
plex pedigrees, in hopes of reducing the underlying het-
erogeneity among BP linkage samples. Although our
strategy restricted recruitment to a relatively smallnumber
of families, we have potentially attained a more homo-
geneous group for detection of linkage. These families
consisted of probands with BPI, the most severe form of
the illness, and other affected members with either BPI or
the clinically less-severe form of the illness, BPII. Given
potential genetic heterogeneity among these diagnostic
classiﬁcations, we also analyzed a BPI-only subset of fami-
lies ( ) with ARPs that were informative for link-np 22
age, which should have further reduced heterogeneity.
Although none of the analyses provided a linkage sig-
nal with a genomewide P value !.05, four chromosomes
showed NPL signals 12.2 in the larger 41-family analy-
sis: chromosome 1q23.3 ( [D1S484]), chro-NPLp 2.46
mosome 3p23 ( [D3S1277]), chromosomeNPLp 2.22
11q12 ( [D11S4191]), and chromosomeNPLp 2.35
18q22.2 ( [D18S61]). For the BPI-only sub-NPLp 2.22
set of 22 pedigrees, our strongest signal was achieved
at chromosome 3p23 (D3S1277), with an NPL score of
2.46. Follow-up genotyping with additional markers
had the greatest impact on signals observed in the 22-
family BPI-only subset: in chromosome 1q23.3, theNPL
score increased from 1.867 to 3.045; in chromosome
3p23, the NPL score increased from 2.457 to 2.850;
and in chromosome 18q, the NPL score increased from
1.792 to 2.439.
We should emphasize the choices made for recruit-
ment and phenotype restrictions. The ﬁeld of BP genetic
discovery has been fraught with weak and inconsistent
ﬁndings. Realizing that a major source of this problem
is likely to be heterogeneity across families, we pursued
strategies to maximize the similarity of our families with
respect to genetic etiology. Thus, the ﬁrst feature of our
study was to focus on the Ashkenazi population, since
there may be a reduced number of founders compared
with outbred populations and therefore potentially less
allelic and locus heterogeneity for the same phenotype.
The second feature is more fundamental: that of phe-
notype identiﬁcation and classiﬁcation. Most previous
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Figure 4 Summary of linkage ﬁndings for BP on chromosome 18
studies have included several diagnostic categories at
once, often considering BPI, BPII, and, sometimes, re-
current unipolar depression or schizoaffective disorders
as “affected” for linkage analyses, with no tabulation
of the distribution of these diagnoses within families.
BPI is characterized by at least one full manic or mixed
episode and usually at least one full major depressive
episode. Psychotic symptoms occur in ∼60% of indi-
viduals with BP (Goodwin and Jamison 1990; Potash
et al. 2001, 2003; A. E. Pulver, unpublished data) and
can occur during the depressive, manic, or mixed epi-
sodes in BPI. BPII is characterized by at least one full
depressive episode, and one or more hypomanic epi-
sodes. The DSM-IV deﬁnes a hypomanic episode as “a
distinct period during which there is an abnormally and
persistently elevated, expansive or irritable mood that
lasts at least 4 days” (American Psychiatric Association
1994). A hypomanic episode differs from a manic epi-
sode in the following respects: (1) it does not cause
marked impairment in social or work functioning; (2)
it does not require hospitalization; and (3) it does not
include psychotic features. Patients frequently have ex-
perienced a feeling of well-being and thus do not identify
the episode as part of a disorder (Cassano et al. 1999;
Benazzi 2001). Therefore, information from informants
about the affected individual can be particularly impor-
tant to diagnosing BPII, and this has been our approach.
However, considering these differences between BPI and
BPII criteria, diagnosis of BPII is often more difﬁcult than
for BPI, and the diagnoses have different reliabilities
and sensitivities, making misclassiﬁcation rates variable
across those designated as “affected” in an analysis. In
general, the less-severe disorders are more difﬁcult to
diagnose reliably (Andreasen et al. 1981). For this rea-
son, we feel it is important to attempt subset analyses
restricted to the BPI phenotype, which may have a dis-
tinct genetic etiology and which also has the least mis-
classiﬁcation potential among these diagnoses.
The advantages and disadvantages to this approach
depend on the underlying nature of the genetic etiology.
If there are genes that predispose to general phenotypes
common across the BPI and BPII diagnoses, then a
“lumping” approach may be more powerful. However,
families typically have not been selected for a particular
subphenotype, which would be the most efﬁcient ap-
proach if this scenario were true. The advantages of
BPI-only subset analyses are that a more reliable pheno-
type should reduce “noise” introduced by misclassiﬁca-
tion and, furthermore, that particular genes may predis-
pose to particular features that distinguish these diag-
noses. In this scenario, the “lumping” approach would
introduce genetic heterogeneity and limit resolution of
any particular gene.
The linkage signals in these Ashkenazi families do not
overlap well with the meta-analyses of previous BP ge-
nome scans, consisting mostly of outbred populations
(Badner and Gershon 2002; Segurado et al. 2003), ex-
cept for the 18q ﬁnding, which lies in a region previously
linked to a BP locus in several other studies (see ﬁg. 4).
Also, although not as strong as our 18q peak, a linkage
signal in the 18p region was observed that has also been
implicated in other studies (ﬁg. 4). Both putative chro-
mosome 18 loci have been associated with P-O-O link-
age effects, suggesting imprinting or some other parent-
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speciﬁc effect. The pattern and mechanism of parental
inheritance are unclear, and such determination is com-
plicated by the often-confused notions of parental origin
based on phenotype, versus parental origin based on
genotype. Many previous studies have stratiﬁed families
according to unilateral inheritance from a particular
parent on the basis of the diagnosis of the parent, as
well as on the basis of shown linkage to a chromosome
18 locus in one or the other stratiﬁed group. This is
quite different from observing which parental chromo-
somes are shared in affected individuals, regardless of
the observable phenotype in a parent. We must be clear
in our discussion of P-O-O effects to distinguish these
methods. We believe that the parental chromosome–
sharing approach is more speciﬁc to the hypothesis of
P-O-O effects, and thus we evaluated the potential for
parent-speciﬁc effects in our sample through both para-
metric and model-free analyses that focused on the pa-
rental origin of marker alleles. We found no compelling
evidence for a P-O-O effect in the 18q linkage region,
but we did observe paternal inheritance (maternal im-
printing) in 18p. Our inability to distinguish a P-O-O
effect at 18q22 is consistent with other studies, in that
results have been ambivalent. For example, McMahon
et al. found evidence of linkage to paternal chromo-
somes at 18q via one IBD analysis, but they also found
evidence supporting maternal inheritance in stratiﬁed
IBD analyses of the same data (McMahon et al. 1997)
Our chromosome 1q, 3p, 11p, and 18q ﬁndings are
each in the proximity of previous linkage to BP and/or
SZ. Kelsoe et al. found linkage to a BP locus on 3p21
in a set of 20 North American families (Kelsoe et al.
2001). The peak signal in that study was ∼20 Mb from
the peak in the present study, but the intervals of signal
overlap well between these two studies. Several reports
have shown linkage to 11p15 (Egeland et al. 1987; Smyth
et al. 1996; Craddock and Jones 1999; Serretti et al.
2000; Sklar et al. 2002; Dick et al. 2003; McInnis et
al. 2003a; Zandi et al. 2003), which is near the linkage
signal observed in our BPI-restricted set. Most recently,
Zandi et al. (2003) found a peak NPL score of 2.96 at
D11S1923, ∼3 Mb from our signal, with largely over-
lapping linkage intervals. This region harbors the can-
didate genes tyrosine hydroxylase (TH), which has been
inconsistently implicated in BP (Smyth et al. 1996), and
brain-derived neurotrophic factor (BDNF), also incon-
sistently implicated through candidate-gene studies as a
susceptibility locus for both SZ and BP (Sklar et al.
2002; Green and Craddock 2003; Hong et al. 2003;
Fanous et al. 2004).
On the q arm of chromosome 11, several linkage
ﬁndings for SZ and affective disorders have been re-
ported, although many are more telomeric than our sig-
nal in the overall set of 41 families (St. Clair et al. 1990;
Nanko et al. 1992; Maziade et al. 1995; Blackwood et
al. 2001; Gurling et al. 2001). Our chromosome 1 signal
overlaps with a putative SZ locus identiﬁed in 22 Celtic
Canadian families at 1q21 (Brzustowicz et al. 2000,
2002). This region has also been implicated in two other
SZ linkage studies of American and European families
(Shaw et al. 1998; Gurling et al. 2001), as well as in a
study of Taiwanese families (Hwu et al. 2003). At least
two candidate genes in this region have shown evidence
for association with SZ and/or psychosis, although not
conclusively: the neuronal small conductance calcium-
activated potassium channel (KCNN3) gene (Ritsner et
al. 2003) and the G-protein signaling 4 (RGS4) gene
(Chowdari et al. 2002). It is interesting to note that the
RGS4 gene has been shown to be underexpressed in the
cerebral cortex of schizophrenics (Mirnics et al. 2001).
The 1q region has also been implicated in SZ and af-
fective disorders on the basis of a 1:11 translocation in
a Scottish family (St. Clair et al. 1990; Blackwood et
al. 2001), although this occurs at 1q42, ∼70 Mb away
from our signal. Although there have been no BP ﬁnd-
ings in this region of chromosome 1, the overlap of a
SZ signal highlights the growing evidence of shared sus-
ceptibility between BP and SZ, which has been noted for
several other chromosomes (Berrettini 2000). In par-
ticular, association evidence for KCNN3 has focused on
dimensions of SZ (Ritsner et al. 2003), and it is possible
that susceptibility to a dimension that is shared between
patients with BPI and those with SZ is controlled by
the same gene.
The small size of our data set has limited our ability
to detect linkage signals. To pursue our ﬁndings by use
of linkage, we would need to gather further data from
the current families, add additional families by use of
the same ascertainment methods, and/or increase the
density of markers. We have shown the improvement
resulting from increased density and will continue in
this vein. However, recruitment of additional family
members in the study pedigrees and the ascertainment
of new multiplex pedigrees has proven extremely dif-
ﬁcult. Another strategy that we propose is to focus link-
age efforts on BP-related clinical phenotypes that are
themselves familial and are also relevant to aspects of
the SZ phenotype, such as mania or psychosis. This
would provide a larger set of families for linkage analy-
sis, with potentially more homogeneous genetic etiolo-
gies, and this strategy ﬁts well with the growing evidence
of overlapping linkage results in SZ and BP.
Finally, given the evidence that LD studies can have
greater power and resolution than linkage (Risch and
Merikangas 1996) and given the emerging high-through-
put genotyping technology for SNP analyses, we also
recommend shifting strategies for BPI gene discovery
toward designs optimized for association strategies. For
example, although we recruited ARPs with BPI from
only 41 families of Ashkenazi descent, we have collected
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over 340 Ashkenazi parent/child trios with a BPI pro-
band. Therefore, collection of relatively homogeneous
groups in appropriately powered sizes is feasible for LD
and direct association analyses. From a pragmatic as
well as a scientiﬁc perspective, association designs and
analytic techniques may be the most fruitful avenue of
discovery.
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